Highest-materiality recent filing
Rein Therapeutics prices $50M public offering of 50M shares at $1.00/share
Gross proceeds $50M from 50M shares at $1.00; net proceeds ~$46.1M after discounts and expenses.
Rein Therapeutics issues $2.875M in unsecured notes to institutional investors at 20% OID
Issued $2.875M aggregate principal notes for $2.3M net cash (20% original issue discount).
FDA lifts clinical hold on Rein Therapeutics' Phase 2 trial of LTI-03 for IPF
FDA lifted full clinical hold after Rein's Complete Response submission; agency confirmed all concerns resolved.
Rein Therapeutics receives EMA authorization to begin Phase 2 trial of LTI-03 for IPF
European Medicines Agency approved Phase 2 RENEW trial at clinical sites in Germany and Poland.
FDA confirmed MCH/H findings in GLP rat studies are not dose-limiting for proposed 24-week LTI-03 protocol at doses up to 10 mg/day in IPF patients.
Rein Therapeutics secures up to $6.0M in prepaid advances from Yorkville; second $1.0M tranche drawn
Entered Pre-Paid Advance Agreement with Yorkville for up to $6.0M over 12 months; initial $1.0M advance closed July 29, 2025.
Rein Therapeutics gets UK MHRA nod for Phase 2 IPF trial of LTI-03
UK MHRA authorized Phase 2 'RENEW' trial of LTI-03 for idiopathic pulmonary fibrosis (IPF).
Rein Therapeutics enters up to $21M financing with Yorkville via PPA and SEPA
Pre-Paid Advance Agreement: up to $6M; initial $1M advance at 95% net ($0.95M); 8% annual interest rising to 18% on default.
FDA placed Phase 2 RENEW trial of LTI-03 on clinical hold on July 8, 2025 via formal letter.
Rein Therapeutics pauses US enrollment in Phase 2 RENEW trial due to FDA clinical hold
FDA placed clinical hold on Phase 2 RENEW trial of LTI-03 on June 10, 2025; US enrollment and dosing paused.
Rein Therapeutics Q1 net loss $5.5M; Phase 2 IPF trial initiated
Net loss $5.5M ($0.25/shr) vs $7.1M ($0.86/shr) year ago; revenue not reported.
Rein Therapeutics raises ~$5.05M via warrant exercises, exchanges, and private placement
Holders exercise 2023 and 2024 warrants for 902,929 shares at reduced price of $1.60 per share.
Rein Therapeutics auditor Marcum resigns, CBIZ appointed; going concern noted
Marcum LLP resigned as independent auditor on April 16, 2025; CBIZ CPAs P.C. engaged by Audit Committee.
Aileron Therapeutics reports Q3 net loss of $5.8M; Phase 1b LTI-03 shows positive biomarker data
Net loss of $5.8M ($0.27 per share) compared to $1.8M ($0.40) in Q3 2023; R&D expenses increased to $3.7M from $0.1M.
Aileron Q2 2024 net loss $8.9M; positive Phase 1b data for LTI-03 in IPF
Net loss of $8.9M ($0.45 per share) vs $1.8M in Q2 2023; R&D expenses surged to $3.7M from $0.2M.
Aileron Therapeutics appoints Timothy Cunningham as interim CFO after Charles Garner departure
Charles Garner departed as CFO on May 15, 2024; Timothy Cunningham appointed interim CFO effective May 16, 2024.
Aileron posts Q1 net loss of $7.1M; positive Phase 1b data for LTI-03 in IPF
Q1 net loss $7.1M ($0.86/share) vs $4.8M ($1.05) in Q1 2023; R&D expenses rose to $3.5M from $1.8M.
Aileron reports positive LTI-03 Phase 1b Cohort 1 IPF data; cash $12.0M
7 of 8 biomarkers showed positive trend; 3 statistically significant: GAL-7 (p=0.0014), TSLP (p=0.0223), Col-1α1 (p=0.0489).
Aileron Therapeutics prices ~$20M registered direct offering of stock and warrants
4,273,505 shares and accompanying warrants sold at combined $4.68/unit; gross proceeds ~$20M, net ~$17.9M.
the Board of Directors of Aileron Therapeutics, Inc. (the “Company”) appointed Timothy M. Cunningham, a consultant at Danforth Advisors, LLC (“Danforth”), as interim chief financial officer, effective as of May 16, 2024.
Mr. Garner's departure from the Company on May 15, 2024.
Max materiality 0.85 · Median 0.65 · Most common event other_material